[{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"893adf5f-401b-45ed-b55a-95592085576f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874194","created_at":"2021-05-05T11:52:46.095Z","updated_at":"2024-07-02T16:35:02.356Z","phase":"Phase 1/2","brief_title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","source_id_and_acronym":"NCT04874194","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RUNX1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-21"},{"id":"a40edb33-4956-4fcb-af35-db7081c0b606","acronym":"","url":"https://clinicaltrials.gov/study/NCT06328179","created_at":"2024-03-25T17:36:14.935Z","updated_at":"2024-07-02T16:35:12.972Z","phase":"","brief_title":"Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.","source_id_and_acronym":"NCT06328179","lead_sponsor":"Huai'an First People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-03-25"},{"id":"63d174f5-1045-41f8-a030-f399abb4d1dd","acronym":"NCI-2016-00073","url":"https://clinicaltrials.gov/study/NCT02697344","created_at":"2021-01-18T13:10:03.223Z","updated_at":"2024-07-02T16:35:25.022Z","phase":"Phase 1","brief_title":"Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma","source_id_and_acronym":"NCT02697344 - NCI-2016-00073","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • CRBN • MAPK1","pipe":" | ","alterations":" BCL2 expression • CRBN expression","tags":["BCL2 • CRBN • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • CRBN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 10/26/2018","primary_completion_date":" 10/26/2018","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2023-12-28"},{"id":"2a514802-0bd5-42d1-abc9-294d1a4f3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT06133088","created_at":"2023-11-15T19:16:06.349Z","updated_at":"2024-07-02T16:35:29.099Z","phase":"Phase 2","brief_title":"Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.","source_id_and_acronym":"NCT06133088","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" CDK6 • LRPPRC","pipe":"","alterations":" ","tags":["CDK6 • LRPPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • R-(-)-gossypol (AT 101)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-11-15"},{"id":"759ba1b6-e6e6-4f22-81f3-e0016eb2b1d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01633541","created_at":"2021-01-18T07:01:11.806Z","updated_at":"2024-07-02T16:35:42.408Z","phase":"Phase 2","brief_title":"Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer","source_id_and_acronym":"NCT01633541","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel • R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 11/06/2021","primary_completion_date":" 11/06/2021","study_txt":" Completion: 11/06/2021","study_completion_date":" 11/06/2021","last_update_posted":"2023-07-20"},{"id":"c5f8fab6-c86d-4fbe-a8fb-aecc5ef0282c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02979366","created_at":"2021-01-18T14:39:22.062Z","updated_at":"2024-07-02T16:36:10.230Z","phase":"Phase 1","brief_title":"Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT02979366","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MIK665"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 03/15/2017","start_date":" 03/15/2017","primary_txt":" Primary completion: 05/11/2020","primary_completion_date":" 05/11/2020","study_txt":" Completion: 05/11/2020","study_completion_date":" 05/11/2020","last_update_posted":"2022-05-18"},{"id":"3dc09b40-82a5-425d-b8e9-5b1b7d8b100e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00462943","created_at":"2021-12-28T22:53:39.815Z","updated_at":"2024-07-02T16:36:19.138Z","phase":"Phase 2","brief_title":"Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML","source_id_and_acronym":"NCT00462943","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 03/07/2007","start_date":" 03/07/2007","primary_txt":" Primary completion: 08/04/2009","primary_completion_date":" 08/04/2009","study_txt":" Completion: 06/27/2013","study_completion_date":" 06/27/2013","last_update_posted":"2021-12-28"},{"id":"c888a839-4434-4bf4-97af-0865b3e560f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00999401","created_at":"2021-01-18T03:54:26.432Z","updated_at":"2024-07-02T16:36:19.263Z","phase":"Phase 1","brief_title":"A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00999401","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapacitabine (CYC682) • seliciclib (CYC202)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 07/16/2019","primary_completion_date":" 07/16/2019","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2021-12-22"},{"id":"e42a85e3-8a8f-4ba5-b42b-6faaef554669","acronym":"","url":"https://clinicaltrials.gov/study/NCT00375219","created_at":"2021-11-11T18:45:16.493Z","updated_at":"2024-07-02T16:36:20.742Z","phase":"Phase 2","brief_title":"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation","source_id_and_acronym":"NCT00375219","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 09/20/2006","start_date":" 09/20/2006","primary_txt":" Primary completion: 03/23/2010","primary_completion_date":" 03/23/2010","study_txt":" Completion: 06/28/2013","study_completion_date":" 06/28/2013","last_update_posted":"2021-11-15"},{"id":"bf75e380-cf06-45ab-9526-c6dc47a6700e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505995","created_at":"2021-01-18T21:36:19.252Z","updated_at":"2024-07-02T16:36:42.207Z","phase":"","brief_title":"Azacitidine and Homoharringtonine in JMML","source_id_and_acronym":"NCT04505995","lead_sponsor":"Fourth Military Medical University","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2020-08-10"},{"id":"3a95cb99-a207-4584-bf34-fd1b90df2dbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00540722","created_at":"2021-01-18T01:57:56.081Z","updated_at":"2024-07-02T16:37:18.969Z","phase":"Phase 2","brief_title":"Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme","source_id_and_acronym":"NCT00540722","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R-(-)-gossypol (AT 101)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-08-11"}]